The European Medicines Commission has granted marketing authorization for Genvoya, this innovative triple therapy treatment in a single daily tablet against infection with the type 1 AIDS virus (HIV-1), said in a statement, Gilead, the lab that makes it.
“With access to appropriate treatment, patients with HIV today have the potential to live almost as long as the general population. However, research shows they are at an increased risk of age-related and treatment-related comorbidities, which means that preserving long-term health should be a priority when making treatment decisions, ” said Anton Pozniak, director of the HIV department, Chelsea and Westminster Hospital in London, UK.
AIDS in France
An essential health announcement, to fight this disease, because if today antiretrovirals are effective in reducing the risk of HIV infection in HIV-negative people, each year more than 6,000 new HIV infections are discovered in France. People are mainly infected through sexual intercourse. The National Institute for Public Health Surveillance (INVS) estimates that 30,000 to 40,000 people are unaware that they are HIV-positive. According to the World Health Organization, with more than 34 million deaths to date, the AIDS continues to be a major public health problem. At the end of 2014, there were an estimated 36.9 million people living with HIV.
Read also:
HIV: antiretrovirals would protect children while breastfeeding
HIV: how does it work in the body?
A vaginal ring could help protect women from HIV
